ABT vs PFE Stock Comparison

Abbott Laboratories and Pfizer Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$187.98B
P/E
40.0x
Revenue (TTM)
$48.23B
Div. yield
2.32%
Medical Devices Healthcare
5 wins
PFE Pfizer Inc
$28.90 -1.1% 1M +12.1% 1Y
Market cap
$164.73B
P/E
40.8x
Revenue (TTM)
$63.63B
Div. yield
5.95%
Pharmaceuticals Healthcare
7 wins

Head to Head

12 decided of 12

Pfizer leads on 7 of the 12 questions below (Pfizer 7, Abbott Laboratories 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTPFELeader
Larger companyMarket capitalisation $187.98B $164.73B ABT
Cheaper on earningsLower P/E, profitable companies only 40.0x 40.8x ABT
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 9.8x PFE
Faster revenue growthRevenue growth, trailing twelve months +10.0% +1.3% ABT
More profitableNet margin, trailing twelve months 9.7% 6.3% ABT
Better return on capitalReturn on invested capital 5.7% 12.3% PFE
Less leveragedLower net debt / EBITDA 2.5x 1.9x PFE
Higher dividend yieldTrailing dividend yield 2.32% 5.95% PFE
Better 1-year returnPrice return, last 12 months -16.0% +12.1% PFE
Better 5-year returnAnnualised price return, 5 years -3.3%/yr -10.3%/yr ABT
Less volatileAnnualised volatility, 1 year 28.5% 21.7% PFE
Higher overall scoreMean of the five percentile scores vs peers 56/100 68/100 PFE

Percentile Scorecard

ABTPFE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTPFE
Valuation 74 #65 of 243 95 #37 of 660
Growth 26 #168 of 228 37 #392 of 619
Profitability 82 #41 of 222 92 #50 of 595
Financial Health 33 #167 of 248 25 #516 of 683
Shareholder Returns 65 #56 of 158 91 #44 of 459
Overall 56 68
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • PFE ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTPFESPY
1 month +5.4%-1.1% -2.0%
3 months -2.4%+7.9% -2.8%
6 months +28.5%+14.1% +2.0%
Year to date -13.4%+16.1% +10.6%
1 year -16.0%+12.1% +12.2%
3 years +11.8%-1.2% +68.1%
3 years, per year +3.8%-0.4% +18.9%
5 years -15.5%-41.9% +61.4%
5 years, per year -3.3%-10.3% +10.1%
10 years +170.4%-11.3% +248.5%
10 years, per year +10.5%-1.2% +13.3%

Risk

MeasureABTPFESPY
Volatility, 1Y 28.5%21.7% 13.6%
Downside volatility, 1Y 27.8%21.9% 13.9%
Beta vs S&P 500, 1Y 0.070.26 1.00
Return / volatility, 1Y -0.560.56 0.90
Max drawdown, 5Y -41.6%-64.8% -25.4%
From 52-week high -16.9%-6.1% -3.2%
52-week high $130.59$30.79 $779.14
52-week low $82.56$23.67 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTPFE
P/E now vs peer median 40.0xmedian 26.5x 40.8xmedian 17.0x
P/S now vs peer median 3.9xmedian 2.7x 2.6xmedian 8.4x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 8.2xmedian 14.6x
P/FCF now vs peer median 27.8xmedian 25.4x 14.0xmedian 19.0x
P/B now vs peer median 3.6xmedian 2.5x 1.8xmedian 2.0x
PEG now vs peer median -13.92median 0.98 -1.47median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTPFE
Revenue $48.23B $63.63B
Gross profit $27.46B $46.69B
Operating income $6.65B $19.40B
Net income $4.70B $4.06B
Free cash flow $6.76B $11.79B
R&D $3.31B $11.52B
EPS (diluted) $2.70 $0.70
Cash & equivalents $4.05B $1.82B
Total debt $31.16B $62.67B
Shares (diluted) 1.74B 5.75B
Enterprise value $162.45B $112.38B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTPFE
P/E 40.0x 40.8x
P/FCF 27.8x 14.0x
P/Operating cash flow 21.2x 11.6x
P/S 3.9x 2.6x
P/B 3.6x 1.8x
P/Tangible book 5.9x 3.8x
EV/EBITDA 20.3x 8.2x
EV/EBIT 32.3x 11.0x
EV/Revenue 4.5x 3.3x
EV/FCF 31.8x 18.1x
EV/Operating cash flow 24.3x 15.0x
PEG (3Y EPS CAGR) -13.92 -1.47

Growth

14 metrics
MetricABTPFE
Revenue growth (1Y) 10.0% 1.3%
Revenue CAGR (3Y) 6.5% -3.2%
Gross profit growth (1Y) 12.1% 1.3%
Gross profit CAGR (3Y) 7.8% 2.7%
Operating income growth (1Y) -13.8% -4.3%
Operating income CAGR (3Y) 3.5% 7.4%
Net income growth (1Y) -66.4% -58.9%
Net income CAGR (3Y) -3.1% -27.2%
EPS growth (1Y) -66.1% -59.2%
EPS CAGR (3Y) -2.9% -27.7%
Operating cash flow growth (1Y) -2.9% 8.4%
Operating cash flow CAGR (3Y) 10.6% 5.6%
Free cash flow growth (1Y) -2.3% 13.6%
Free cash flow CAGR (3Y) 14.6% 13.0%

Profitability

14 metrics
MetricABTPFE
Gross margin 56.9% 73.4%
EBITDA margin 21.9% 40.7%
Operating margin 13.8% 30.5%
Pretax margin 13.6% 6.7%
Net margin 9.7% 6.3%
FCF margin 14.0% 18.5%
Operating cash flow margin 18.4% 22.3%
Return on equity 9.1% 4.7%
Return on assets 4.3% 2.0%
Return on invested capital 5.7% 12.3%
Return on capital employed 7.2% 11.3%
Asset turnover 0.4x 0.3x
Cash conversion (OCF / net income) 1.9x 3.5x
Stock comp / revenue 1.5% 1.7%

Financial Health

11 metrics
MetricABTPFE
Debt / assets 28.8% 30.6%
Debt / equity 0.6x 0.7x
Net debt / EBITDA 2.5x 1.9x
Debt / FCF 4.6x 5.3x
Liabilities / assets 52.3% 56.4%
Equity / assets 47.7% 43.6%
Interest coverage 6.7x –
Current ratio 1.5x 1.4x
Quick ratio 0.8x 0.9x
Cash ratio 0.3x 0.4x
Altman Z-score 3.36 2.34

Shareholder Returns

7 metrics
MetricABTPFE
Dividend yield 2.3% 6.0%
Net buyback yield 0.7% –
Shareholder yield 3.0% 6.0%
Payout ratio (earnings) 92.0% 241.2%
Payout ratio (FCF) 64.0% 83.1%
Dividend growth (1Y) 6.9% 0.9%
Dividend CAGR (3Y) 7.4% 2.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTPFE
Forward P/E 19.1xFY2026 9.8xFY2026
EPS, next fiscal year $5.69FY2026 $2.95FY2026
EPS growth, next FY +10.5%FY2026 -8.4%FY2026
EPS growth, the year after +10.2% -5.8%
Revenue, next fiscal year $52.99BFY2026 $61.46BFY2026
Revenue growth, next FY +19.5%FY2026 -1.8%FY2026
Revenue growth, the year after -2.3% +4.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTPFE
Held by institutions 79.2% 66.9%
Institutions holding 2,983 2,842
Change in shares held, QoQ +0.3% +2.0%
Institutions buying 1,261 1,327
Institutions selling 1,379 1,206
Buyers to sellers 0.91 1.10

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTPFE
ABT 1.00 0.27
PFE 0.27 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT and PFE?

Abbott Laboratories (ABT) is the largest by market capitalisation: Abbott Laboratories (ABT) $187.98B, Pfizer (PFE) $164.73B.

Which stock is cheaper, ABT and PFE?

Abbott Laboratories (ABT) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 40.0x, Pfizer (PFE) 40.8x). On next year's consensus earnings, Pfizer (PFE) is cheapest (Abbott Laboratories (ABT) 19.1x, Pfizer (PFE) 9.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Pfizer (PFE) +1.3%.

Which company is more profitable?

Abbott Laboratories (ABT) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Pfizer (PFE) 6.3%). On return on invested capital, Pfizer (PFE) leads (Abbott Laboratories (ABT) 5.7%, Pfizer (PFE) 12.3%).

Which stock has performed better?

Over the past year Pfizer (PFE) returned the most: Abbott Laboratories (ABT) -16.0%, Pfizer (PFE) +12.1%. Over five years, Abbott Laboratories (ABT) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Pfizer (PFE) -10.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Pfizer (PFE) has the highest dividend yield: Abbott Laboratories (ABT) 2.32%, Pfizer (PFE) 5.95%.

Which stock is riskier?

By one-year price volatility, Pfizer (PFE) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Pfizer (PFE) 21.7%). Volatility measures how widely the price swings, not the risk of the business.

Do ABT and PFE move together?

Their daily returns over the past year have a correlation of 0.27, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, ABT and PFE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Pfizer (PFE) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.